Immitra Bio
Cell & Gene Therapy
Funding and backers
Total raised
$2.7M
1 round on record
Latest round
$2.7M
Venture round · Aug 2026 · 3 mo ago
Team
11-50
employees, estimated range
Backers
1
Occident
The money's age
Fresh money
3 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 3
Raised a round Venture round $2.7M · led by Backbone
Dec 2024
Website went live first capture in the Wayback Machine
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2026 | $2.7M | Backbone lead | ggba.swiss |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Universal access to high quality delivery platforms for developers of genomics medicines. A new path for biotechnologists.
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for…
About Us We build the medicines we wish existed CPTx is a genetic medicines company redefining how we treat disease using immune-silent…
Signadori Bio is a preclinical stage biopharmaceutical company developing a next generation in vivo monocyte immunotherapy to treat solid…
Innorna is a clinical-stage biotechnology company engineering mRNA-based medicines to treat chronic diseases, power in vivo…
Reforgene is a Chinese biotechnology company developing cell and gene therapies. Its research covers ex vivo and in vivo gene editing, gene…
Financials
Total raised
$2.7M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2026 | $2.7M | Details |
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
OccidentVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely